An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Nintedanib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 09 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 11 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.